A look at Part D enrollment trends for 2026
Just over 56 million people are enrolled in Medicare Part D, with the share of those securing coverage through Medicare...
Recent Trends in GLP-1 Use and Spending in Medicare
Ahead of the Trump administration’s planned expansion of Medicare coverage for GLP-1s to treat obesity through temporary models and the...
CMMI proposes new models to lower drug prices in Parts B, D
The Medicare Innovation Center has proposed two drug pricing models that would lower the cost of certain drugs to reflect...
What to Know About Pharmacy Benefit Managers (PBMs) and Federal Efforts at Regulation
The price of prescription drugs in the U.S. continues to be a concerning issue to the public, with KFF polling...
CMS launching payment model to boost access to GLP-1s
The Trump administration has unveiled yet another new payment model, this one focused on the cost of GLP-1 therapies. The...
People with Medicare Will Face Higher Costs for Some Orphan Drugs Due to Changes in the New Tax and Budget Law
Editorial Note: This brief was originally published on September 24, 2025 and was updated on October 20, 2025 to include...
What to Know About the Medicare Open Enrollment Period and Medicare Coverage Options
Medicare is the federal health insurance program for 69 million people ages 65 and over and younger adults with long-term...
Elevance stock dips with plans to exit standalone Part D, some Medicare Advantage markets
Elevance Health’s shares took a dip on Thursday as the company reaffirmed its outlook for 2025 and revealed plans to...
CMS may add Part B drugs to negotiations under draft guidance
The Trump administration has issued new draft guidance for the third cycle of Medicare drug price negotiations. The proposals seek...
Biden names Ozempic, Wegovy for price negotiation program
The Biden administration unveiled its list of 15 drugs, which include GLP-1 drugs Ozempic, Wegovy and Rybelsus, for the second...
